Kintor Pharmaceutical Limited (HKG:9939)

Kintor Pharmaceutical Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	5	-	-	34.23	-
Revenue	5	-	-	34.23	-
Cost of Revenue	9.73	42.23	-	-	-
Gross Profit	-4.73	-42.23	-	34.23	-
Selling, General & Admin	88.38	96.03	152.58	117.95	85.69
Research & Development	78.14	938.91	827.97	767.94	328.76
Other Operating Expenses	-19.95	-7.49	-11.43	-16.96	-14.71
Operating Expenses	147.78	1,027	969.12	868.93	399.74
Operating Income	-152.51	-1,070	-969.12	-834.7	-399.74
Interest Expense	-9.28	-9.69	-8.19	-2.49	-3.38
Interest & Investment Income	4.21	13.08	6.88	12.05	10.42
Earnings From Equity Investments	-1.43	0.05	-0.57	-	-
Currency Exchange Gain (Loss)	3.73	-3.13	16.33	-17.63	-118.29
EBT Excluding Unusual Items	-155.28	-1,069	-954.67	-842.77	-511
Gain (Loss) on Sale of Investments	0	0.49	2	0.78	2.13
Gain (Loss) on Sale of Assets	0	0.01	-0.62	-0.11	0.64
Pretax Income	-155.27	-1,069	-953.28	-842.1	-508.23
Income Tax Expense	0.02	-8.04	1.09	-	0.07
Net Income	-155.29	-1,061	-954.37	-842.1	-508.3
Net Income to Common	-155.29	-1,061	-954.37	-842.1	-508.3
Shares Outstanding (Basic)	431	429	377	356	309
Shares Outstanding (Diluted)	431	429	377	356	309
Shares Change (YoY)	0.39%	13.94%	5.66%	15.21%	29.24%
EPS (Basic)	-0.36	-2.47	-2.53	-2.36	-1.64
EPS (Diluted)	-0.36	-2.47	-2.53	-2.36	-1.64
Free Cash Flow	-200.62	-390.3	-988.73	-1,128	-449.92
Free Cash Flow Per Share	-0.47	-0.91	-2.63	-3.16	-1.45
Gross Margin	-94.60%	-	-	100.00%	-
Operating Margin	-3050.18%	-	-	-2438.42%	-
Profit Margin	-3105.84%	-	-	-2460.04%	-
Free Cash Flow Margin	-4012.36%	-	-	-3294.09%	-
EBITDA	-139.36	-1,056	-956.45	-827.97	-396.33
D&A For EBITDA	13.15	13.85	12.68	6.73	3.42
EBIT	-152.51	-1,070	-969.12	-834.7	-399.74

Updated Sep 26, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.